Paratek Pharmaceuticals (NASDAQ:PRTK) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. The brokerage currently has a $15.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 11.11% from the company’s current price.
According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
Other analysts have also issued research reports about the stock. ValuEngine lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $39.25.
Shares of Paratek Pharmaceuticals (PRTK) opened at $13.50 on Thursday. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49. Paratek Pharmaceuticals has a 12 month low of $11.85 and a 12 month high of $29.00. The firm has a market cap of $422.92, a price-to-earnings ratio of -3.62 and a beta of 0.21.
In other news, VP Adam Woodrow sold 14,333 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $13.87, for a total transaction of $198,798.71. Following the completion of the transaction, the vice president now owns 62,367 shares of the company’s stock, valued at $865,030.29. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Robert S. Radie sold 3,000 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $14.22, for a total transaction of $42,660.00. Following the transaction, the director now directly owns 9,330 shares of the company’s stock, valued at approximately $132,672.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,664 shares of company stock valued at $573,226. Corporate insiders own 4.90% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Great West Life Assurance Co. Can acquired a new position in shares of Paratek Pharmaceuticals during the third quarter valued at $104,000. SG Americas Securities LLC acquired a new position in shares of Paratek Pharmaceuticals during the third quarter valued at $123,000. Sei Investments Co. boosted its holdings in shares of Paratek Pharmaceuticals by 2,069.3% during the third quarter. Sei Investments Co. now owns 8,981 shares of the specialty pharmaceutical company’s stock valued at $225,000 after acquiring an additional 8,567 shares during the period. Loeb Partners Corp acquired a new position in shares of Paratek Pharmaceuticals during the third quarter valued at $226,000. Finally, Belpointe Asset Management LLC acquired a new position in shares of Paratek Pharmaceuticals during the third quarter valued at $228,000. 74.55% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/22/zacks-investment-research-upgrades-paratek-pharmaceuticals-prtk-to-buy.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.